AnaptysBio’s Phase 1b Study for Celiac Disease

Biotech company AnaptysBio is conducting a phase 1b clinical trial testing the safety, tolerability, and potential signals of efficacy of the investigational drug ANB033. ANB033 is a monoclonal antibody being studied for its potential to reduce intestinal inflammation, improve intestinal health, and alleviate symptoms caused by gluten exposure in adults living with celiac disease.

Requirements:

  • 18-70 years old
  • Diagnosed with celiac disease by biopsy at least 12 months ago
  • Attempting a gluten-free diet for at least 12 months

Additional eligibility criteria will apply.

Participation in the study will last approximately 9 months. Study activities may include:

  • Three subcutaneous injections of the study drug or placebo
  • Two upper endoscopies about 2 or 3 months apart
  • 14-day gluten challenge for some participants
  • Daily electronic symptom diary

Compensation for time and travel is available.

If you are interested in participating, please answer the questions below.

If you are eligible to move forward, a representative from the study site will contact you to further assess your eligibility and discuss study participation.

"*" indicates required fields

Name*
How old are you?*
Do you have a celiac disease diagnosis that has been confirmed by small bowel biopsy at least 12 months ago?*
Have you attempted a gluten-free diet for at least 12 months?*
How would you describe your celiac disease symptoms on a regular basis while following your normal gluten-free diet?*
Which study location would you prefer to visit to take part in this study? Please select the study site that is closest to you.*
Privacy Policy*
Consent*
If you have any questions, please contact [email protected].